A research team at Cincinnati Children’s Hospital Medical Center has received a $150,000 grant to repurpose Barasertib as a potential treatment for Idiopathic Pulmonary Fibrosis. Using a computational drug discovery pipeline coupled with preclinical validation studies, Anil Jegga, DVM, MRes,
Integrative Computational Screening and Systems Biology Approaches Lead to Grant for Potential Idiopathic Pulmonary Fibrosis Treatment
